BMRA Company Profile and Key Details

Q: Who are the executives of BMRA?

Mr. Robert W. CarlsonChief Commercial OfficerMr. Allen C. BarbieriExecutive Vice-Chairman & Corporation Sec.Hans BoehringerSenior Vice President of POC R&DMr. Zackary S. IraniChairman & Chief Executive OfficerMr. Steven SloanInterim Chief Financial Officer & TreasurerMs. Lucy Liu Ph.D.Director of Manufacturing & Technical OperationsMr. Gary Lu CPAPrincipal Accounting Officer & Chief Financial OfficerMr. Gary LuChief Financial Officer

NASDAQ : BMRA

Biomerica

$2.55

0.18+7.59%

Open: 1:23 PM

52.85

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Biomerica, Inc. (BMRA) stock surged +7.59%, trading at $2.55 on NASDAQ, up from the previous close of $2.37. The stock opened at $2.50, fluctuating between $2.41 and $2.76 in the recent session.

Stock Snapshot

2.37

Prev. Close

7.32M

Market Cap

2.41

Day Low

-1.67

P/E Ratio

-1.53

EPS (TTM)

-0.32

Cash Flow per Share

2.5

Open

2.87M

Number of Shares

2.755

Day High

94.26%

Free Float in %

0.46

Book Value

2.24M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Dec 22, 2025	2.31	2.47	2.31	2.37	22.03K
Dec 19, 2025	2.38	2.43	2.30	2.31	26.25K
Dec 17, 2025	2.39	2.39	2.30	2.39	3.25K
Dec 16, 2025	2.47	2.47	2.37	2.37	18.82K
Dec 15, 2025	2.59	2.59	2.42	2.47	13.06K
Dec 12, 2025	2.53	2.61	2.50	2.58	15.1K
Dec 11, 2025	2.58	2.67	2.50	2.58	53.97K
Dec 10, 2025	2.44	2.57	2.43	2.50	7.9K
Dec 09, 2025	2.45	2.58	2.45	2.54	9.72K
Dec 08, 2025	2.34	2.60	2.30	2.49	78.83K
Dec 05, 2025	2.30	2.38	2.30	2.34	8.61K
Dec 04, 2025	2.30	2.35	2.26	2.30	8.49K
Dec 03, 2025	2.30	2.35	2.27	2.31	24.51K
Dec 02, 2025	2.32	2.34	2.27	2.34	8.42K
Dec 01, 2025	2.31	2.34	2.26	2.26	27.98K
Nov 28, 2025	2.37	2.39	2.33	2.37	4.55K
Nov 26, 2025	2.35	2.38	2.32	2.32	5.25K
Nov 25, 2025	2.31	2.40	2.11	2.39	28.25K
Nov 24, 2025	2.23	2.37	2.18	2.29	15.41K
Nov 21, 2025	2.27	2.32	2.23	2.23	14.81K

Contact Details

Irvine, CA 92614

United States

https://www.biomerica.com 949 645 2111

About Company

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Stock Peers

BRKRP

15.71+4.36%

Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A$375.87 SWAV

-0.08-0.02%

ShockWave Medical, Inc.$334.75 PODD

1.95+0.67%

Insulet Corporation$291.57 UFPT

0.27+0.12%

UFP Technologies, Inc.$229.67 IRTC

5.48+3.15%

iRhythm Technologies, Inc.$179.65 ALGN

1.59+1.01%

Align Technology, Inc.$159.28 TMDX

1.68+1.32%

TransMedics Group, Inc.$129.35 IRMD

-0.06-0.06%

IRadimed Corporation$97.13 NARI

Inari Medical, Inc.$79.97 ESTA

2.195+2.95%

Establishment Labs Holdings Inc.$76.61

Company Overview

Biomerica, Inc. (NASDAQ:BMRA) closed at $2.55 USD, gaining $0.18 (7.59%) from the previous close of $2.37. The stock is currently mid-range between its 52-week high and low $2.11 and $10.16. With a market capitalization of about $7.32 million, Biomerica, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.06). Key stats such as the average daily volume over the past year has been around 92.89 thousand shares, trading with heavier-than-usual volume. Headquartered in Irvine, CA, Biomerica, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Zackary S. Irani, the company employs approximately 64 people and listed since September 07, 1984. Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 -0.98%, SMA50 -7.53%, SMA200 -27.75%). The stock’s 14-day RSI is 45.68 (neutral), while the ATR of 0.14 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -76.67% below its high and over 13.94% above its low. Average 10-day trading volume of 16.68 thousand shares is below the 3-month average of 92.29 thousand, indicating normal recent market interest.

Valuation Metrics

Biomerica, Inc. trades at a P/E ratio of -1.69, slightly below the S&P 500 average, with a price-to-sales ratio of 1.38 and a price-to-book ratio of 1.2 suggesting the stock is closer to book value. The P/FCF stands at -2.43, also below market averages.

Dividend & Fair Value

Biomerica, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.25. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Biomerica, Inc. generated EPS of -$1.53 over the past year. Five-year average earnings growth is -3.3%. Biomerica, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended April 14, 2022, missed forecasts by -90.0%. The prior quarter beat by 12.5%. Over the last six quarters, Apple has recorded several small beats. These include 30.0% in January 14, 2021.

Shareholding & Insider Activity

Biomerica, Inc. has 2.55 million shares outstanding. The public float is 2.64 million shares, elevated short interest at 17.87% of float. This equals 427.73 thousand shares. The short ratio is 0.25 days. Institutional investors hold 3.54% of the float. Insiders own 9.16%. Irani Zackary S. holds 1.02 million shares, MOORE JANET TRUST DTD 8/21/98 has 635.98 thousand shares and MOORE JANET has 140.72 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Biomerica generated $5.31M in revenue, or $2.31 per share. Gross margin was 9.38%, operating margin -96.72%, and net profit margin -93.64%. Returns are negative, with ROA at -83.65% and ROE at -121.14%.
On valuation metrics, Biomerica trades at a P/E of -1.69, P/S of 1.38 and P/B of 1.20. The current ratio is 3.48 and quick ratio is 2.61. Operationally, the company’s inventory turnover is 2.88 and cash conversion cycle is 158.11 days. Debt-to-equity is 0.07, supported by a cash flow-to-debt ratio of -7.41.

Quarterly Financial Highlights

For the quarter ended May 31, 2025, Biomerica posted revenue of $5.31M, down slightly from $5.42M in the prior quarter. Gross profit was $498.00K (margin 9.38%). Operating income was - $5.14M (margin -96.7%). Net income was- $4.97M (EPS - $2.16).
The company ended the quarter with $2.40M in cash and short-term investments, a total debt of $458.00K, and net debt of - $1.94M. Total assets were $5.95M, with equity of $4.11M. Financials further reflected weakness, with operating cash flow of - $3.84M, free cash flow of - $3.88M, and capital expenditures of - $37.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Biomerica, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 3.8%, with price expected at $2.46 by January 05, 2026, within a range of $2.36 to $2.56 3-Month Outlook: Projected rise of 145.15%, reaching $5.81 by March 20, 2026, with a range of $5.37 to $6.20. 1-Year Outlook: Projected loss of -38.4%, with price at $1.46 by December 22, 2026, within a range of $0.00 to $0.34.

Key Takeaways

Biomerica, Inc. (NASDAQ:BMRA) shares are flat -1.29% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Biomerica, Inc. trading at a premium to the broader market with a P/E of -1.69. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $10.25, suggesting 332.49% upside. Our AI forecast model points to short-term strength (3.8% over two weeks), a medium-term rise (145.15% over three months), and a longer-term loss (-38.4% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Biomerica, Inc. (BMRA) stock price?

Biomerica, Inc. (NASDAQ: BMRA) stock price is $2.55 in the last trading session. During the trading session, BMRA stock reached the peak price of $2.76 while $2.41 was the lowest point it dropped to. The percentage change in BMRA stock occurred in the recent session was 7.59% while the dollar amount for the price change in BMRA stock was $0.18.

BMRA's industry and sector of operation?

The NASDAQ listed BMRA is part of Medical - Devices industry that operates in the broader Healthcare sector. Biomerica, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of BMRA?

Mr. Robert W. Carlson
Chief Commercial Officer
Mr. Allen C. Barbieri
Executive Vice-Chairman & Corporation Sec.
Hans Boehringer
Senior Vice President of POC R&D
Mr. Zackary S. Irani
Chairman & Chief Executive Officer
Mr. Steven Sloan
Interim Chief Financial Officer & Treasurer
Ms. Lucy Liu Ph.D.
Director of Manufacturing & Technical Operations
Mr. Gary Lu CPA
Principal Accounting Officer & Chief Financial Officer
Mr. Gary Lu
Chief Financial Officer

How BMRA did perform over past 52-week?

BMRA's closing price is 13.94% higher than its 52-week low of $2.11 where as its distance from 52-week high of $10.16 is -76.67%.

How many employees does BMRA have?

Number of BMRA employees currently stands at 64.

Link for BMRA official website?

Official Website of BMRA is: https://www.biomerica.com

How do I contact BMRA?

BMRA could be contacted at phone 949 645 2111 and can also be accessed through its website. BMRA operates from 17571 Von Karman Avenue, Irvine, CA 92614, United States.

How many shares of BMRA are traded daily?

BMRA stock volume for the day was 2.24M shares. The average number of BMRA shares traded daily for last 3 months was 92.89K.

What is the market cap of BMRA currently?

The market value of BMRA currently stands at $7.32M with its latest stock price at $2.55 and 2.87M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	64
Beta	0.06
Sales or Revenue	$5.31M
5Y Sales Change%	2.512%
Fiscal Year Ends	May
Sector	Healthcare
Industry	Medical - Devices

BMRA Company Profile and Key Details

Biomerica

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Earnings & Analyst Outlook

Shareholding & Insider Activity

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook